MIRA INFORM REPORT

 

 

Report Date :

17.11.2014

 

IDENTIFICATION DETAILS

 

Name :

CAPSUGEL DE MEXICO S DE RL DE CV

 

 

Registered Office :

Carretera Veracruz 1030 Colonia San Jose Maravillas 72225 Prolongacion Diagonal Defensores Y Parque Industrial Puebla 2000 Camino A Resurreccion Puebla

 

 

Country :

Mexico

 

 

Year of Establishment :

2007  

 

 

Legal Form :

Sociedad de Responsabilidad Limitada de Capital Variable

 

 

Line of Business :

Provider of Hard Capsules

 

 

No. of Employees :

70

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

Mexico

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

MEXICO - ECONOMIC OVERVIEW

 

Mexico's $1.3 trillion economy has become increasingly oriented toward manufacturing in the 20 years since the North American Free Trade Agreement (NAFTA) entered into force. Per capita income is roughly one-third that of the US; income distribution remains highly unequal. Mexico has become the United States' second-largest export market and third-largest source of imports. In 2013, two-way merchandise trade reached nearly $507 billion. Mexico has free trade agreements with over 50 countries including Guatemala, Honduras, El Salvador, the European Free Trade Area, and Japan - putting more than 90% of trade under free trade agreements. In 2012 Mexico formally joined the Trans-Pacific Partnership negotiations and formed the Pacific Alliance with Peru, Colombia and Chile. Mexico's current government, led by President Enrique PENA NIETO, emphasized economic reforms during its first year in office, passing education, energy, financial, fiscal and telecommunications reform legislation. The three-party "Pact for Mexico" reform agenda aims to improve competitiveness and economic growth across the Mexican economy.

 

Source : CIA

 

 

 

 


 

company Name and address

Name

Capsugel De Mexico S De Rl De CV

Address in the order:

NA

Legal Name:

CAPSUGEL DE MEXICO S. R.L. DE C.V.

Trade Name:

CAPSUGEL DE MEXICO

RFC:

CME061103KG5

Date Created:

1931

Date Incorporated:

2007   

Legal Address:

CARRETERA VERACRUZ 1030 COLONIA SAN JOSE MARAVILLAS 72225 PROLONGACION DIAGONAL DEFENSORES Y PARQUE INDUSTRIAL PUEBLA 2000 CAMINO A RESURRECCION PUEBLA, MEXICO

Operative Address:

Insurgentes Sur No. 826, Piso 11 Sur
Colonia del Valle
03100, México, D.F.
México

Telephone:

(55) 5543-2787

Fax:

(55) 5543-2787

Legal Form:

Sociedad de Responsabilidad Limitada de Capital Variable

Email:

arturo.gonzalez@capsugel.com

Registered in:

142: CAMARA NACIONAL DE LA INDUSTRIA DE TRANSFORMACION / Mexico

Website:

http://www.capsugel.es/en/about/facilities/

Manager:

Teresa Rodriguez

Staff:

70

Activity:

Provider of hard capsules

SIC Codes:

5162 5169

NAICS Codes:

 

424610 424690

BANKS

BANK

BANCO SANTANDER

The company does not publish its banking information.

 

HISTORY

The company was incorporated in 2007.

Capugel was founded in 1931 in Detroit, Michigan as a division of Parke-Davis, after Arthur Colton designed a machine which simultaneously manufactured the body and caps of a hard gelatin capsule, and fit them together. In 1970, Parke-Davis, including Capsugel, was acquired by Warner Lambert, which was acquired by Pfizer in 2000. On 1 August 2011, Pfizer sold Capsugel to global investment firm Kohlberg Kravis Roberts for $2.38 billion.

 

MAIN ACTIVITY

Capsugel is the world’s leading provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries.

Products/Services:

It offers a comprehensive array of products and services, from hard gelatin, vegetarian and liquid-filled capsules, to innovative R&D equipment and liquid formulations as part of its Licaps Drug Delivery System.

Brands:

Coni-Snap ®, Vcaps® y Vcaps®Plus, DRcaps™, Press-fit® y  Xpress-fit™, Licaps®,  Plantcaps™, DBcaps®, Ocean Caps™.

Competitors:

SINTETIC MEXICANA
TECNOVAM

Sales:

Wholesale

Clients:

Capsugel Brasil Importacao
Brazil

Capsugel Belgium Bvba
Belgium

Laboratorios Pfizer Ltda
Brazil

QUIMICOS CAMPOTA Y CIA LTDA
Colombia

Suppliers

P. B. GELATINS UK LTD
TREFORESTPONTYPRIDD MGM
CF37 5SU UNITED KING

WEISHARDT INTERNATIONAL
ROND-POINT GEORGES JOLIMAITRE
BP 259 81305 GRAULHET CEDEX FRANCE

Operations Area:

National & International

The company imports from

UK, France, Hong Kong, Taiwan

The company exports to

Colombia, Brazil, Belgium

The company employs

71 employees

Payments:

Regular-made on a 45 day basis

 

LOCATION

Headquarters  :

Insurgentes Sur No. 826, Piso 11 Sur
Colonia del Valle
03100, México, D.F.
México

Branches:

Av. 18 de Noviembre 1030-A  Puebla, Pue. 72290, Mexico

Business Industry:

Companies in this industry manufacture and process pharmaceutical products.

Demand for pharmaceuticals is driven by the desire to cure illness and disease. The profitability of individual companies depends on their ability to discover and market new drugs. Large companies benefit from their economies of scale in research, manufacturing, and marketing. Small companies can compete effectively by specializing in drugs that target one or two specific ailments and by partnering with larger drugmakers.

Drugs are chemicals with beneficial biological activity. Modern drug development is an outgrowth of recent research into the specific causes of illness and disease, coupled with advances in chemistry and industrial technology that allow scientists to manufacture chemicals to improve these conditions.

 

GROUP STRUCTURE AND SUBSIDIARY COMPANIES

Listed at the stock exchange:

NO

Capital:

NA

Shareholders %:

Capsugel de Mexico, S. de R.L. de C.V. operates as a subsidiary of:

Capsugel, Inc.
412 Mount Kemble Avenue
Suite 200-C
Morristown, NJ 07960
United States

This company was acquired in 2011 by:

Kohlberg Kravis Roberts & Co.
9 West 57th Street
Suite 4200
New York, New York 10019
U.S.

 

Management:

Mr. Guido Edouard Driesen, Regional President
Teresa Rodriguez, Manager
Gabriela Pérez, Capital Project Head
Yolanda Sánchez, Customer Service

Related Companies:

Capsugel has research and development labs in:

Illkirch, France
Greenwood, South Carolina
Colmar, France
Bornem, Belgium
It has major production facilities in:

The Americas

Greenwood, South Carolina

Europe

Ploërmel, France
Colmar, France
Bornem, Belgium
Asia

Sagamahara, Japan
Suzhou, China
Dharuhera, India
Ayuthaya, Thailand
Cibinong, Indonesia

 

FINANCIAL INFORMATION

This is a private company which does not make its financial public. The following information was provided by outside sources.

2013 USD

 

Turnover

53 000 000

Net Income

1 800 000

Net Worth

4 000 000

Liabilities

500 000

Cash Flow

Good

Capsugel, Inc (USA)

2013

Revenue

USD 880 000 000

Kohlberg Kravis Roberts & Co. L.P. (KKR)

2013 All numbers in thousands

Total Revenue

662,93

Cost of Revenue

- 

Gross Profit

662,93

Operating Expenses

 

Research Development

- 

Selling General and Administrative

1,767,138 

Non Recurring

- 

Others

- 

Total Operating Expenses

- 

Operating Income or Loss

(1,104,208)

Income from Continuing Operations

 

Total Other Income/Expenses Net

8,996,362 

Earnings Before Interest And Taxes

7,991,770 

Interest Expense

99,616

Income Before Tax

7,892,154 

Income Tax Expense

37,926

Minority Interest

(7,163,002)

Net Income From Continuing Ops

691,226

Non-recurring Events

 

Discontinued Operations

- 

Extraordinary Items

- 

Effect Of Accounting Changes

- 

Other Items

- 

Net Income

691,226

Preferred Stock And Other Adjustments

- 

Net Income Applicable To Common Shares

691,226

Over the past 34 years, KKR has invested in more than 185 transactions with a total value of more than $435 billion. KKR's current private equity portfolio includes over 60 portfolio companies with over $210 billion of annual revenues and more than 900,000 employees.

 

SUMMARY

Capsugel is the world's leading provider of hard capsules and an innovator in drug delivery systems for the pharmaceutical, OTC and health and nutrition industries.

The company has 7 years in the Mexican market and more than 50 years worldwide.

It was a subsidiary of Pfizer, Inc and was acquired by KKR in 2011.

This Mexican division exports mainly to Brazil and imports from Europe and Asia.

There are no negative.

 

RISK INFORMATION

DEBTS

Controlled

PAYMENTS

Regular

CASH FLOW

Normal

SUGGESTED CREDIT LINE

USD 500 000

 

ENTERVIEW

NAME

Yolanda Sánchez

POSITION

Customer Service

COMMENTS

She confirmed address, activity and refused to confirm more data.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.65

UK Pound

1

Rs.96.54

Euro

1

Rs.76.70

 

INFORMATION DETAILS

 

Analysis Done by :

RAS

 

 

Report Prepared by :

NIT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity.

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised.

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.